Autoimmunity and peginterferon therapy for polycythemia vera
In July this year (2026), a French group published a review article titled ‘Autoimmunity and peginterferon therapy for polycythemia vera‘.
“In this narrative review, we provide an overview of how peginterferon can induce autoimmunity in genetically susceptible individuals with pre-existing subclinical autoimmunity. Pre-treatment risk assessment, including personal/family history of autoimmune disease and consideration of baseline thyroid function and anti-GAD antibodies in high-risk patients, may identify those at elevated risk for irreversible complications, particularly Type 1 diabetes. Targeted clinical and laboratory monitoring throughout therapy and for 12–24 months post-cessation can enable early detection and appropriate intervention.”
The full review article is in HemaSphere so it is free to access in full.
Targeted antibody treatments offer hope for MPN patients with a CALR mutation
Researchers presented Phase 1 results for Incyte’s INCA33989 mutant-CALR antibody
at the European Hematology Association Congress in June, with trial participants in
both ET and MF showing encouraging early responses. Australia’s A/Professor David
Ross from South Australia has prepared this expert review of the findings for patients,
including upcoming clinical trials targeting the CALR mutation, offering clear insights
into what may be an important step forward in the treatment of CALR-positive ET and
MF.
